haematology
Blood cancers

Perspectives on the use of ibrutinib for relapsed/refractory mantle cell lymphoma: Professor Martin Dreyling

Sponsored by Janssen-Cilag Pty Ltd

In this podcast, Professor Martin Dreyling from Germany discusses the role of ibrutinib as standard of care for relapsed or refractory mantle cell lymphoma. He also describes how extended follow-up data for ibrutinib has influenced his treatment decisions.  

Already a member?

Login to keep reading.


OR
© 2021 the limbic